- Home
- NDRA
as 11-15-2024 4:00pm EST
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 5.1M | IPO Year: | 2017 |
| Target Price: | $14000.00 | AVG Volume (30 days): | 709.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -131.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.41 - $4882.50 | Next Earning Date: | 11-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of ENDRA Life Sciences Inc. (NDRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| UBS Group AG | NDRA | N/A | Aug 27 '24 | Buy | $0.00 | 0 | $0.00 | 146,012 | |
| UBS Group AG | NDRA | 10% Owner | Aug 27 '24 | Buy | $0.55 | 3,715 | $2,051.79 | 146,012 |
Latest ENDRA Life Sciences Inc. News
NDRA Breaking Stock News: Dive into NDRA Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Business Wire
6 days ago
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
Business Wire
12 days ago
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
MT Newswires
a month ago
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires
a month ago
Sector Update: Health Care
MT Newswires
a month ago
ENDRA Life Sciences Shares Soar After Launch of Postmarket Trial for TAEUS Liver System
Business Wire
a month ago
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
Business Wire
3 months ago
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
Compare NDRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NDRA ENDRA Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.